- Home
- VTRS vs EXEL Comparison
VTRS vs EXEL Comparison
Compare VTRS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTRS
- EXEL
- Stock Information
- Founded
- VTRS 1961
- EXEL 1994
- Country
- VTRS United States
- EXEL United States
- Employees
- VTRS N/A
- EXEL N/A
- Industry
- VTRS Medicinal Chemicals and Botanical Products
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTRS Health Care
- EXEL Health Care
- Exchange
- VTRS Nasdaq
- EXEL Nasdaq
- Market Cap
- VTRS 12.2B
- EXEL 10.4B
- IPO Year
- VTRS N/A
- EXEL 2000
- Fundamental
- Price
- VTRS $10.10
- EXEL $40.99
- Analyst Decision
- VTRS Hold
- EXEL Buy
- Analyst Count
- VTRS 6
- EXEL 24
- Target Price
- VTRS $11.17
- EXEL $44.73
- AVG Volume (30 Days)
- VTRS 8.7M
- EXEL 3.2M
- Earning Date
- VTRS 11-06-2025
- EXEL 11-04-2025
- Dividend Yield
- VTRS 4.72%
- EXEL N/A
- EPS Growth
- VTRS N/A
- EXEL 53.55
- EPS
- VTRS N/A
- EXEL 2.38
- Revenue
- VTRS $14,124,400,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- VTRS N/A
- EXEL $9.14
- Revenue Next Year
- VTRS $1.61
- EXEL $12.51
- P/E Ratio
- VTRS N/A
- EXEL $17.42
- Revenue Growth
- VTRS N/A
- EXEL 9.93
- 52 Week Low
- VTRS $6.85
- EXEL $31.90
- 52 Week High
- VTRS $13.55
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- VTRS 46.06
- EXEL 59.59
- Support Level
- VTRS $9.92
- EXEL $36.00
- Resistance Level
- VTRS $10.95
- EXEL $41.55
- Average True Range (ATR)
- VTRS 0.28
- EXEL 1.40
- MACD
- VTRS -0.03
- EXEL 0.32
- Stochastic Oscillator
- VTRS 17.96
- EXEL 91.61
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.